Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11520209,IC(50),"A selected compound UR-12715 (49c) showed an IC(50) of 8 nM in the in vitro PAF-induced aggregation assay, and an ID(50) of 29 microg/kg in the in vivo PAF-induced hypotension test in normotensive rats.",Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11520209/),nM,8,12656,DB00233,Aminosalicylic Acid
,11520209,ID(50),"A selected compound UR-12715 (49c) showed an IC(50) of 8 nM in the in vitro PAF-induced aggregation assay, and an ID(50) of 29 microg/kg in the in vivo PAF-induced hypotension test in normotensive rats.",Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11520209/),[μg] / [kg],29,12657,DB00233,Aminosalicylic Acid
,3557190,distribution half-life,After an intravenous injection of 3.26 mmol 5ASA serum concentrations fell rapidly with a distribution half-life of 17 +/- 2 min and an elimination half-life of 42 +/- 5 min.,Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),min,17,12912,DB00233,Aminosalicylic Acid
,3557190,elimination half-life,After an intravenous injection of 3.26 mmol 5ASA serum concentrations fell rapidly with a distribution half-life of 17 +/- 2 min and an elimination half-life of 42 +/- 5 min.,Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),min,42,12913,DB00233,Aminosalicylic Acid
,3557190,Bioavailabilities,"Bioavailabilities which ranged from 19% for ileocaecal release to 75% for release in the upper gastrointestinal tract, were calculated from areas under the serum concentration curves.",Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),%,19,12914,DB00233,Aminosalicylic Acid
,3557190,Bioavailabilities,"Bioavailabilities which ranged from 19% for ileocaecal release to 75% for release in the upper gastrointestinal tract, were calculated from areas under the serum concentration curves.",Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),%,75,12915,DB00233,Aminosalicylic Acid
,3557190,Urinary excretion,"Urinary excretion of 5ASA and its acetyl metabolite over 48 hours was 78%, 52%, 55%, and 21% respectively of the dose given intravenously and orally for gastric, small intestinal and ileocaecal release.",Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),%,78,12916,DB00233,Aminosalicylic Acid
,3557190,Urinary excretion,"Urinary excretion of 5ASA and its acetyl metabolite over 48 hours was 78%, 52%, 55%, and 21% respectively of the dose given intravenously and orally for gastric, small intestinal and ileocaecal release.",Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),%,52,12917,DB00233,Aminosalicylic Acid
,3557190,Urinary excretion,"Urinary excretion of 5ASA and its acetyl metabolite over 48 hours was 78%, 52%, 55%, and 21% respectively of the dose given intravenously and orally for gastric, small intestinal and ileocaecal release.",Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),%,55,12918,DB00233,Aminosalicylic Acid
,3557190,Urinary excretion,"Urinary excretion of 5ASA and its acetyl metabolite over 48 hours was 78%, 52%, 55%, and 21% respectively of the dose given intravenously and orally for gastric, small intestinal and ileocaecal release.",Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),%,21,12919,DB00233,Aminosalicylic Acid
,18691952,flow rate,Plasma samples were analyzed after protein precipitation with methanol and the two analytes were separated using a C18 column with a mobile phase composed of 17.5 mmol/L acetic acid (pH 3.3):acetonitrile=85:15 (v/v) at 0.2 mL/min flow rate.,Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),[ml] / [min],0.2,14661,DB00233,Aminosalicylic Acid
,18691952,m/,"Selective detection was performed by tandem mass spectrometry with electrospray source, operating in negative ionization mode and in multiple reaction monitoring acquisition (m/z 152-->108 for 5-ASA; m/z 194-->150 and 194-->107 for N-Ac-5-ASA).",Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),,152,14662,DB00233,Aminosalicylic Acid
,18691952,m/,"Selective detection was performed by tandem mass spectrometry with electrospray source, operating in negative ionization mode and in multiple reaction monitoring acquisition (m/z 152-->108 for 5-ASA; m/z 194-->150 and 194-->107 for N-Ac-5-ASA).",Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),,108,14663,DB00233,Aminosalicylic Acid
,18691952,m/z,"Selective detection was performed by tandem mass spectrometry with electrospray source, operating in negative ionization mode and in multiple reaction monitoring acquisition (m/z 152-->108 for 5-ASA; m/z 194-->150 and 194-->107 for N-Ac-5-ASA).",Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),,194,14664,DB00233,Aminosalicylic Acid
,18691952,m/z,"Selective detection was performed by tandem mass spectrometry with electrospray source, operating in negative ionization mode and in multiple reaction monitoring acquisition (m/z 152-->108 for 5-ASA; m/z 194-->150 and 194-->107 for N-Ac-5-ASA).",Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),,150,14665,DB00233,Aminosalicylic Acid
,18691952,m/z,"Selective detection was performed by tandem mass spectrometry with electrospray source, operating in negative ionization mode and in multiple reaction monitoring acquisition (m/z 152-->108 for 5-ASA; m/z 194-->150 and 194-->107 for N-Ac-5-ASA).",Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),,194,14666,DB00233,Aminosalicylic Acid
,18691952,m/z,"Selective detection was performed by tandem mass spectrometry with electrospray source, operating in negative ionization mode and in multiple reaction monitoring acquisition (m/z 152-->108 for 5-ASA; m/z 194-->150 and 194-->107 for N-Ac-5-ASA).",Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),,107,14667,DB00233,Aminosalicylic Acid
>,18691952,overall recoveries,"The overall recoveries (n=6) at three tested concentration levels (i.e. 100, 1000 and 4000 ng/mL) were respectively >90% for 5-ASA and >95% for N-Ac-5-ASA (R.S.D.% < or = 10%).",Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),%,90,14668,DB00233,Aminosalicylic Acid
>,18691952,overall recoveries,"The overall recoveries (n=6) at three tested concentration levels (i.e. 100, 1000 and 4000 ng/mL) were respectively >90% for 5-ASA and >95% for N-Ac-5-ASA (R.S.D.% < or = 10%).",Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),%,95,14669,DB00233,Aminosalicylic Acid
< or =,18691952,overall recoveries,"The overall recoveries (n=6) at three tested concentration levels (i.e. 100, 1000 and 4000 ng/mL) were respectively >90% for 5-ASA and >95% for N-Ac-5-ASA (R.S.D.% < or = 10%).",Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),%,10,14670,DB00233,Aminosalicylic Acid
,18691952,maximum concentration,The mean maximum concentration levels were 680 ng/mL for 5-ASA and 1240 ng/mL for N-Ac-5-ASA and the kinetic profiles were in agreement with previous studies.,Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),[ng] / [ml],680,14671,DB00233,Aminosalicylic Acid
,18691952,maximum concentration,The mean maximum concentration levels were 680 ng/mL for 5-ASA and 1240 ng/mL for N-Ac-5-ASA and the kinetic profiles were in agreement with previous studies.,Development and validation of a HPLC-ESI-MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691952/),[ng] / [ml],1240,14672,DB00233,Aminosalicylic Acid
,32588106,MIC,"Peak PAS concentrations over minimum inhibitory concentration of 100, which is required for bactericidal activity are achieved in 53%, 65%, 72% and 84% of patients administered 12, 14, 16 and 20 g once-daily PASER, respectively, when MIC is 1 mg/L.",Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32588106/),[mg] / [l],1,16335,DB00233,Aminosalicylic Acid
,10759687,serum area under curve (AUC),"Serum concentrations and 24 h urinary excretion of 5ASA and N-acetyl 5ASA increased as the oral dose of mesalazine was increased from 1.2 g through 2.4 g to 4.8 g daily (serum area under curve (AUC):5ASA = 3. 9, 15.4 and 46.8 microg ml-1 h, P < 0.0001; N-acetyl 5ASA = 17.2, 30. 9 and 57.8 microg ml-1 h, P < 0.0001: urinary excretion: 5ASA = 1.8, 85.5 and 445 mg, P < 0.0001; N-acetyl 5ASA = 250, 524 and 1468 mg, P < 0.0001, respectively).",Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759687/),[h·μg] / [ml],3. 9,24479,DB00233,Aminosalicylic Acid
,10759687,serum area under curve (AUC),"Serum concentrations and 24 h urinary excretion of 5ASA and N-acetyl 5ASA increased as the oral dose of mesalazine was increased from 1.2 g through 2.4 g to 4.8 g daily (serum area under curve (AUC):5ASA = 3. 9, 15.4 and 46.8 microg ml-1 h, P < 0.0001; N-acetyl 5ASA = 17.2, 30. 9 and 57.8 microg ml-1 h, P < 0.0001: urinary excretion: 5ASA = 1.8, 85.5 and 445 mg, P < 0.0001; N-acetyl 5ASA = 250, 524 and 1468 mg, P < 0.0001, respectively).",Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759687/),[h·μg] / [ml],15.4,24480,DB00233,Aminosalicylic Acid
,10759687,serum area under curve (AUC),"Serum concentrations and 24 h urinary excretion of 5ASA and N-acetyl 5ASA increased as the oral dose of mesalazine was increased from 1.2 g through 2.4 g to 4.8 g daily (serum area under curve (AUC):5ASA = 3. 9, 15.4 and 46.8 microg ml-1 h, P < 0.0001; N-acetyl 5ASA = 17.2, 30. 9 and 57.8 microg ml-1 h, P < 0.0001: urinary excretion: 5ASA = 1.8, 85.5 and 445 mg, P < 0.0001; N-acetyl 5ASA = 250, 524 and 1468 mg, P < 0.0001, respectively).",Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759687/),[h·μg] / [ml],46.8,24481,DB00233,Aminosalicylic Acid
,10759687,serum area under curve (AUC),"Serum concentrations and 24 h urinary excretion of 5ASA and N-acetyl 5ASA increased as the oral dose of mesalazine was increased from 1.2 g through 2.4 g to 4.8 g daily (serum area under curve (AUC):5ASA = 3. 9, 15.4 and 46.8 microg ml-1 h, P < 0.0001; N-acetyl 5ASA = 17.2, 30. 9 and 57.8 microg ml-1 h, P < 0.0001: urinary excretion: 5ASA = 1.8, 85.5 and 445 mg, P < 0.0001; N-acetyl 5ASA = 250, 524 and 1468 mg, P < 0.0001, respectively).",Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759687/),[h·μg] / [ml],17.2,24482,DB00233,Aminosalicylic Acid
,10759687,serum area under curve (AUC),"Serum concentrations and 24 h urinary excretion of 5ASA and N-acetyl 5ASA increased as the oral dose of mesalazine was increased from 1.2 g through 2.4 g to 4.8 g daily (serum area under curve (AUC):5ASA = 3. 9, 15.4 and 46.8 microg ml-1 h, P < 0.0001; N-acetyl 5ASA = 17.2, 30. 9 and 57.8 microg ml-1 h, P < 0.0001: urinary excretion: 5ASA = 1.8, 85.5 and 445 mg, P < 0.0001; N-acetyl 5ASA = 250, 524 and 1468 mg, P < 0.0001, respectively).",Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759687/),[h·μg] / [ml],30. 9,24483,DB00233,Aminosalicylic Acid
,10759687,serum area under curve (AUC),"Serum concentrations and 24 h urinary excretion of 5ASA and N-acetyl 5ASA increased as the oral dose of mesalazine was increased from 1.2 g through 2.4 g to 4.8 g daily (serum area under curve (AUC):5ASA = 3. 9, 15.4 and 46.8 microg ml-1 h, P < 0.0001; N-acetyl 5ASA = 17.2, 30. 9 and 57.8 microg ml-1 h, P < 0.0001: urinary excretion: 5ASA = 1.8, 85.5 and 445 mg, P < 0.0001; N-acetyl 5ASA = 250, 524 and 1468 mg, P < 0.0001, respectively).",Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759687/),[h·μg] / [ml],57.8,24484,DB00233,Aminosalicylic Acid
,10759687,urinary excretion,"Serum concentrations and 24 h urinary excretion of 5ASA and N-acetyl 5ASA increased as the oral dose of mesalazine was increased from 1.2 g through 2.4 g to 4.8 g daily (serum area under curve (AUC):5ASA = 3. 9, 15.4 and 46.8 microg ml-1 h, P < 0.0001; N-acetyl 5ASA = 17.2, 30. 9 and 57.8 microg ml-1 h, P < 0.0001: urinary excretion: 5ASA = 1.8, 85.5 and 445 mg, P < 0.0001; N-acetyl 5ASA = 250, 524 and 1468 mg, P < 0.0001, respectively).",Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759687/),mg,250,24485,DB00233,Aminosalicylic Acid
,10759687,urinary excretion,"Serum concentrations and 24 h urinary excretion of 5ASA and N-acetyl 5ASA increased as the oral dose of mesalazine was increased from 1.2 g through 2.4 g to 4.8 g daily (serum area under curve (AUC):5ASA = 3. 9, 15.4 and 46.8 microg ml-1 h, P < 0.0001; N-acetyl 5ASA = 17.2, 30. 9 and 57.8 microg ml-1 h, P < 0.0001: urinary excretion: 5ASA = 1.8, 85.5 and 445 mg, P < 0.0001; N-acetyl 5ASA = 250, 524 and 1468 mg, P < 0.0001, respectively).",Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759687/),mg,52,24486,DB00233,Aminosalicylic Acid
,10759687,urinary excretion,"Serum concentrations and 24 h urinary excretion of 5ASA and N-acetyl 5ASA increased as the oral dose of mesalazine was increased from 1.2 g through 2.4 g to 4.8 g daily (serum area under curve (AUC):5ASA = 3. 9, 15.4 and 46.8 microg ml-1 h, P < 0.0001; N-acetyl 5ASA = 17.2, 30. 9 and 57.8 microg ml-1 h, P < 0.0001: urinary excretion: 5ASA = 1.8, 85.5 and 445 mg, P < 0.0001; N-acetyl 5ASA = 250, 524 and 1468 mg, P < 0.0001, respectively).",Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759687/),mg,146,24487,DB00233,Aminosalicylic Acid
,2034991,faecal water concentration,The faecal water concentration of mesalazine was significantly higher after suppository treatment (55.7 mmol/l) compared with enema treatment (31.7 mmol/l) (p less than 0.01).,Availability of mesalazine (5-aminosalicylic acid) from enemas and suppositories during steady-state conditions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2034991/),[mM] / [l],55.7,27153,DB00233,Aminosalicylic Acid
,2034991,faecal water concentration,The faecal water concentration of mesalazine was significantly higher after suppository treatment (55.7 mmol/l) compared with enema treatment (31.7 mmol/l) (p less than 0.01).,Availability of mesalazine (5-aminosalicylic acid) from enemas and suppositories during steady-state conditions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2034991/),[mM] / [l],31.7,27154,DB00233,Aminosalicylic Acid
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],24.9,28221,DB00233,Aminosalicylic Acid
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[h·mg] / [l],242.3,28222,DB00233,Aminosalicylic Acid
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],65.9,28223,DB00233,Aminosalicylic Acid
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],5.3,28224,DB00233,Aminosalicylic Acid
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],6.6,28225,DB00233,Aminosalicylic Acid
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],4.7,28226,DB00233,Aminosalicylic Acid
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],42.0,28227,DB00233,Aminosalicylic Acid
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],34.5,28228,DB00233,Aminosalicylic Acid
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[h·mg] / [l],242.3,28229,DB00233,Aminosalicylic Acid
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],6.6,28230,DB00233,Aminosalicylic Acid
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[h·mg] / [l],64.4,28231,DB00233,Aminosalicylic Acid
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],4.7,28232,DB00233,Aminosalicylic Acid
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[h·mg] / [l],54.2,28233,DB00233,Aminosalicylic Acid
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],42.0,28234,DB00233,Aminosalicylic Acid
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[h·mg] / [l],196.7,28235,DB00233,Aminosalicylic Acid
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],34.5,28236,DB00233,Aminosalicylic Acid
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[h·mg] / [l],153.5,28237,DB00233,Aminosalicylic Acid
,19723408,area under the plasma concentration-time curve from time 0 to 12 h (AUC(0-12h)),"After steady-state administration of PTH, the mean area under the plasma concentration-time curve from time 0 to 12 h (AUC(0-12h)) was 11.0 +/- 3.7 microg h/ml.",Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19723408/),[h·μg] / [ml],11.0,28848,DB00233,Aminosalicylic Acid
,19723408,T(max),The mean T(max) and t(1/2) were respectively 3.6 h and 2.7 h.,Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19723408/),h,3.6,28849,DB00233,Aminosalicylic Acid
,19723408,t(1/2),The mean T(max) and t(1/2) were respectively 3.6 h and 2.7 h.,Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19723408/),h,2.7,28850,DB00233,Aminosalicylic Acid
,19733518,flow rate,"Chromatographic separation was achieved on a Cosmosil HILIC column using an isocratic mobile phase consisting of ammonium acetate buffer (20mM) and acetonitrile (45:55, v/v) at a flow rate of 200microl/min.",Determination of para-aminohippuric acid (PAH) in human plasma and urine by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19733518/),[μl] / [min],200,29427,DB00233,Aminosalicylic Acid
,19733518,m/z,The transactions monitored were m/z 192.9-->149.1 for PAH and m/z 152.1-->108.1 for IS.,Determination of para-aminohippuric acid (PAH) in human plasma and urine by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19733518/),,192.9,29428,DB00233,Aminosalicylic Acid
,19733518,m/z,The transactions monitored were m/z 192.9-->149.1 for PAH and m/z 152.1-->108.1 for IS.,Determination of para-aminohippuric acid (PAH) in human plasma and urine by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19733518/),,149.1,29429,DB00233,Aminosalicylic Acid
,19733518,m/z,The transactions monitored were m/z 192.9-->149.1 for PAH and m/z 152.1-->108.1 for IS.,Determination of para-aminohippuric acid (PAH) in human plasma and urine by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19733518/),,152.1,29430,DB00233,Aminosalicylic Acid
,31056855,maximum plasma concentration,"The mean maximum plasma concentration and the time to reach the maximum plasma concentration of N-Ac-5-ASA were 2084 ng/mL, 8 hours; 2639 ng/mL, 11 hours, and 2409 ng/mL, 9 hours for fasted, high-fat, and low-fat, respectively.",Effects of Differential Food Patterns on the Pharmacokinetics of Enteric-Coated Mesalazine Tablets in the Same Cohort of Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31056855/),[ng] / [ml],2084,32858,DB00233,Aminosalicylic Acid
,31056855,maximum plasma concentration,"The mean maximum plasma concentration and the time to reach the maximum plasma concentration of N-Ac-5-ASA were 2084 ng/mL, 8 hours; 2639 ng/mL, 11 hours, and 2409 ng/mL, 9 hours for fasted, high-fat, and low-fat, respectively.",Effects of Differential Food Patterns on the Pharmacokinetics of Enteric-Coated Mesalazine Tablets in the Same Cohort of Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31056855/),[ng] / [ml],2409,32859,DB00233,Aminosalicylic Acid
,31056855,time to reach the maximum plasma concentration,"The mean maximum plasma concentration and the time to reach the maximum plasma concentration of N-Ac-5-ASA were 2084 ng/mL, 8 hours; 2639 ng/mL, 11 hours, and 2409 ng/mL, 9 hours for fasted, high-fat, and low-fat, respectively.",Effects of Differential Food Patterns on the Pharmacokinetics of Enteric-Coated Mesalazine Tablets in the Same Cohort of Healthy Chinese Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31056855/),h,11,32860,DB00233,Aminosalicylic Acid
,31056855,time to reach the maximum plasma concentration,"The mean maximum plasma concentration and the time to reach the maximum plasma concentration of N-Ac-5-ASA were 2084 ng/mL, 8 hours; 2639 ng/mL, 11 hours, and 2409 ng/mL, 9 hours for fasted, high-fat, and low-fat, respectively.",Effects of Differential Food Patterns on the Pharmacokinetics of Enteric-Coated Mesalazine Tablets in the Same Cohort of Healthy Chinese Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31056855/),[ng] / [ml],2409,32861,DB00233,Aminosalicylic Acid
,31056855,time to reach the maximum plasma concentration,"The mean maximum plasma concentration and the time to reach the maximum plasma concentration of N-Ac-5-ASA were 2084 ng/mL, 8 hours; 2639 ng/mL, 11 hours, and 2409 ng/mL, 9 hours for fasted, high-fat, and low-fat, respectively.",Effects of Differential Food Patterns on the Pharmacokinetics of Enteric-Coated Mesalazine Tablets in the Same Cohort of Healthy Chinese Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31056855/),h,9,32862,DB00233,Aminosalicylic Acid
,16466733,flow rate,The whole analysis lasted 23 min at the flow rate of 1 ml min(-1).,High-performance liquid-chromatographic determination of 5-aminosalicylic acid and its metabolites in blood plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16466733/),[ml] / [min],1,35576,DB00233,Aminosalicylic Acid
,16466733,LLOQ (LOD),LLOQ (LOD) was estimated 126 (20) pmol ml(-1) of plasma for N-acetyl-5-ASA and 318 (50) pmol ml(-1) of plasma for N-propionyl-5-ASA.,High-performance liquid-chromatographic determination of 5-aminosalicylic acid and its metabolites in blood plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16466733/),[pM] / [ml],126,35577,DB00233,Aminosalicylic Acid
,16466733,LLOQ (LOD),LLOQ (LOD) was estimated 126 (20) pmol ml(-1) of plasma for N-acetyl-5-ASA and 318 (50) pmol ml(-1) of plasma for N-propionyl-5-ASA.,High-performance liquid-chromatographic determination of 5-aminosalicylic acid and its metabolites in blood plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16466733/),[pM] / [ml],318,35578,DB00233,Aminosalicylic Acid
,9169983,time when,"After the oral administration of SASP at the does of 25.0 mg/kg, the mean time when the plasma 5-ASA concentration reaches to its maximum (Tmax) was 9.0 hr.",Application of a colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9169983/),h,9.0,38801,DB00233,Aminosalicylic Acid
,9169983,Tmaxs,"In the case of 5-ASA administered in PCC, at the doses of 12.5 and 25.0 mg/kg, Tmaxs were 5.3 and 5.3 hr, respectively.",Application of a colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9169983/),h,5.3,38802,DB00233,Aminosalicylic Acid
,2908013,plasma levels,SP plasma levels were 17.7 +/- 9.0 ug/ml (range 6.8-36.3 ug/ml) at 6 hours after doses.,[Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908013/),[ug] / [ml],17.7,46626,DB00233,Aminosalicylic Acid
,2908013,plasma levels,"SASP plasma levels were 15.5 +/- 15.4 ug/ml (range 2.1-53.4 ug/ml) at 6 hours after doses, and 14.0 +/- 20.4 ug/ml (range 3.9-70.7 ug/ml) at 12 hours after doses.",[Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908013/),[ug] / [ml],15.5,46627,DB00233,Aminosalicylic Acid
,2908013,plasma levels,"SASP plasma levels were 15.5 +/- 15.4 ug/ml (range 2.1-53.4 ug/ml) at 6 hours after doses, and 14.0 +/- 20.4 ug/ml (range 3.9-70.7 ug/ml) at 12 hours after doses.",[Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908013/),[ug] / [ml],14.0,46628,DB00233,Aminosalicylic Acid
,2908013,24 hours,The 24 hours fecal excretion was 17.4 to 236 mg.,[Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908013/),mg,17.4 to 236,46629,DB00233,Aminosalicylic Acid
,2908013,fecal excretion,The 24 hours fecal excretion was 17.4 to 236 mg.,[Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908013/),mg,17.4 to 236,46630,DB00233,Aminosalicylic Acid
,12526826,bioavailability,"Furthermore, the bioavailability of 5-ASA was estimated to be 0.330 because of the first-pass elimination through both cecum and liver.",Analysis and prediction of absorption behavior of colon-targeted prodrug in rats by GI-transit-absorption model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12526826/),,0.330,49922,DB00233,Aminosalicylic Acid
,15142198,total,The geometric mean total (5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid) urinary excretion values (A(e)%) of Asacol and balsalazide were 19.26 and 19.31% (P = 0.98).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),%,19.26,54223,DB00233,Aminosalicylic Acid
,15142198,urinary excretion,The geometric mean total (5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid) urinary excretion values (A(e)%) of Asacol and balsalazide were 19.26 and 19.31% (P = 0.98).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),%,19.26,54224,DB00233,Aminosalicylic Acid
,15142198,urinary excretion,The geometric mean total (5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid) urinary excretion values (A(e)%) of Asacol and balsalazide were 19.26 and 19.31% (P = 0.98).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),%,19.31,54225,DB00233,Aminosalicylic Acid
,15142198,A(e)%,The geometric mean total (5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid) urinary excretion values (A(e)%) of Asacol and balsalazide were 19.26 and 19.31% (P = 0.98).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),%,19.26,54226,DB00233,Aminosalicylic Acid
,15142198,A(e)%,The geometric mean total (5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid) urinary excretion values (A(e)%) of Asacol and balsalazide were 19.26 and 19.31% (P = 0.98).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),%,19.31,54227,DB00233,Aminosalicylic Acid
,15142198,A(e)%,The geometric mean A(e)% values of 5-aminosalicylic acid for Asacol and balsalazide were 0.39 and 0.37% (P = 0.78); the geometric mean A(e)% values of N-acetyl-5-aminosalicylic acid for Asacol and balsalazide were 18.78 and 18.83% (P = 0.98).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),%,0.39,54228,DB00233,Aminosalicylic Acid
,15142198,A(e)%,The geometric mean A(e)% values of 5-aminosalicylic acid for Asacol and balsalazide were 0.39 and 0.37% (P = 0.78); the geometric mean A(e)% values of N-acetyl-5-aminosalicylic acid for Asacol and balsalazide were 18.78 and 18.83% (P = 0.98).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),%,0.37,54229,DB00233,Aminosalicylic Acid
,15142198,A(e)%,The geometric mean A(e)% values of 5-aminosalicylic acid for Asacol and balsalazide were 0.39 and 0.37% (P = 0.78); the geometric mean A(e)% values of N-acetyl-5-aminosalicylic acid for Asacol and balsalazide were 18.78 and 18.83% (P = 0.98).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),%,18.78,54230,DB00233,Aminosalicylic Acid
,15142198,A(e)%,The geometric mean A(e)% values of 5-aminosalicylic acid for Asacol and balsalazide were 0.39 and 0.37% (P = 0.78); the geometric mean A(e)% values of N-acetyl-5-aminosalicylic acid for Asacol and balsalazide were 18.78 and 18.83% (P = 0.98).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),%,18.83,54231,DB00233,Aminosalicylic Acid
,15142198,AUC(t(last)),The geometric mean 5-aminosalicylic acid AUC(t(last)) values for Asacol and balsalazide were 3295 and 3449 ng h/mL (P = 0.85); the geometric mean N-acetyl-5-aminosalicylic acid AUC(t(last)) values for Asacol and balsalazide were 15 364 and 16 050 ng h/mL (P = 0.69).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),[h·ng] / [ml],3295,54232,DB00233,Aminosalicylic Acid
,15142198,AUC(t(last)),The geometric mean 5-aminosalicylic acid AUC(t(last)) values for Asacol and balsalazide were 3295 and 3449 ng h/mL (P = 0.85); the geometric mean N-acetyl-5-aminosalicylic acid AUC(t(last)) values for Asacol and balsalazide were 15 364 and 16 050 ng h/mL (P = 0.69).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),[h·ng] / [ml],3449,54233,DB00233,Aminosalicylic Acid
,15142198,AUC(t(last)),The geometric mean 5-aminosalicylic acid AUC(t(last)) values for Asacol and balsalazide were 3295 and 3449 ng h/mL (P = 0.85); the geometric mean N-acetyl-5-aminosalicylic acid AUC(t(last)) values for Asacol and balsalazide were 15 364 and 16 050 ng h/mL (P = 0.69).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),[h·ng] / [ml],15 364,54234,DB00233,Aminosalicylic Acid
,15142198,AUC(t(last)),The geometric mean 5-aminosalicylic acid AUC(t(last)) values for Asacol and balsalazide were 3295 and 3449 ng h/mL (P = 0.85); the geometric mean N-acetyl-5-aminosalicylic acid AUC(t(last)) values for Asacol and balsalazide were 15 364 and 16 050 ng h/mL (P = 0.69).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),[h·ng] / [ml],16 050,54235,DB00233,Aminosalicylic Acid
,15142198,C(max),The geometric mean 5-5-aminosalicylic acid C(max) values for Asacol and balsalazide were 319 and 348 ng/mL (P = 0.80); the geometric mean N-acetyl-5-aminosalicylic acid C(max) values for Asacol and balsalazide 927 and 1009 ng/mL (P = 0.67).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),[ng] / [ml],319,54236,DB00233,Aminosalicylic Acid
,15142198,C(max),The geometric mean 5-5-aminosalicylic acid C(max) values for Asacol and balsalazide were 319 and 348 ng/mL (P = 0.80); the geometric mean N-acetyl-5-aminosalicylic acid C(max) values for Asacol and balsalazide 927 and 1009 ng/mL (P = 0.67).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),[ng] / [ml],348,54237,DB00233,Aminosalicylic Acid
,15142198,C(max),The geometric mean 5-5-aminosalicylic acid C(max) values for Asacol and balsalazide were 319 and 348 ng/mL (P = 0.80); the geometric mean N-acetyl-5-aminosalicylic acid C(max) values for Asacol and balsalazide 927 and 1009 ng/mL (P = 0.67).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),[ng] / [ml],927,54238,DB00233,Aminosalicylic Acid
,15142198,C(max),The geometric mean 5-5-aminosalicylic acid C(max) values for Asacol and balsalazide were 319 and 348 ng/mL (P = 0.80); the geometric mean N-acetyl-5-aminosalicylic acid C(max) values for Asacol and balsalazide 927 and 1009 ng/mL (P = 0.67).,"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15142198/),[ng] / [ml],1009,54239,DB00233,Aminosalicylic Acid
,6123257,Peak serum 5-ASA concentration,Peak serum 5-ASA concentration (55 micrograms/ml) was reached in 1 h.,"Absorption, enterohepatic circulation, and excretion of 5-aminosalicylic acid in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6123257/),[μg] / [ml],55,55904,DB00233,Aminosalicylic Acid
,6123257,peak serum concentration,"When sulfapyridine (20 mg) was administered in addition to 5-ASA, 70% of the sulfapyridine was absorbed in the small intestine, peak serum concentration (50 micrograms/ml) was reached in 1 h, and 30% of the administered dose was excreted in the urine in 24 h.","Absorption, enterohepatic circulation, and excretion of 5-aminosalicylic acid in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6123257/),[μg] / [ml],50,55905,DB00233,Aminosalicylic Acid
,21251889,total run time,"The total run time was 9.0 min and the elution of SASP, SP and 5-ASA was at 4.8 min, 2.5 min and 2.0 min, respectively.",Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21251889/),min,9.0,59775,DB00233,Aminosalicylic Acid
,21251889,elution,"The total run time was 9.0 min and the elution of SASP, SP and 5-ASA was at 4.8 min, 2.5 min and 2.0 min, respectively.",Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21251889/),min,4.8,59776,DB00233,Aminosalicylic Acid
,21251889,elution,"The total run time was 9.0 min and the elution of SASP, SP and 5-ASA was at 4.8 min, 2.5 min and 2.0 min, respectively.",Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21251889/),min,2.5,59777,DB00233,Aminosalicylic Acid
,21251889,elution,"The total run time was 9.0 min and the elution of SASP, SP and 5-ASA was at 4.8 min, 2.5 min and 2.0 min, respectively.",Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21251889/),min,2.0,59778,DB00233,Aminosalicylic Acid
,31682027,Cmax,A large interindividual variability was observed for the PAS Cmax (40.42-68.55 mg/L) following 4 g twice daily; (62.69-102.41 mg/L) for 8 g once daily and a similar wide Cmax range found for the metabolites acetyl-PAS and glycine-PAS.,Pharmacokinetics of Para-Aminosalicylic Acid and Its 2 Major Metabolites: A Potential Relationship to the Development of Gastrointestinal Intolerance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31682027/),[mg] / [l],40.42-68.55,59958,DB00233,Aminosalicylic Acid
,31682027,Cmax,A large interindividual variability was observed for the PAS Cmax (40.42-68.55 mg/L) following 4 g twice daily; (62.69-102.41 mg/L) for 8 g once daily and a similar wide Cmax range found for the metabolites acetyl-PAS and glycine-PAS.,Pharmacokinetics of Para-Aminosalicylic Acid and Its 2 Major Metabolites: A Potential Relationship to the Development of Gastrointestinal Intolerance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31682027/),[mg] / [l],62.69-102.41,59959,DB00233,Aminosalicylic Acid
,8104772,local bioavailability,"The local bioavailability in the distal gut lumen, reflected by the 5-aminosalicylic acid concentration in the fecal water, showed comparable values after Pentasa (4.44 mmol/liter) and Salazopyrin (6.25 mmol/liter).",Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104772/),[mM] / [l],4.44,72014,DB00233,Aminosalicylic Acid
,8104772,local bioavailability,"The local bioavailability in the distal gut lumen, reflected by the 5-aminosalicylic acid concentration in the fecal water, showed comparable values after Pentasa (4.44 mmol/liter) and Salazopyrin (6.25 mmol/liter).",Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104772/),[mM] / [l],6.25,72015,DB00233,Aminosalicylic Acid
,8104772,urinary excretion,The urinary excretion of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid was higher after Pentasa than after Salazopyrin (32% vs 25%).,Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104772/),%,32,72016,DB00233,Aminosalicylic Acid
,8104772,urinary excretion,The urinary excretion of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid was higher after Pentasa than after Salazopyrin (32% vs 25%).,Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104772/),%,25,72017,DB00233,Aminosalicylic Acid
,2877884,24-hour recoveries,"The 24-hour recoveries of the drugs were 90.5% and 84.7%, respectively.",5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877884/),%,90.5,80941,DB00233,Aminosalicylic Acid
,2877884,24-hour recoveries,"The 24-hour recoveries of the drugs were 90.5% and 84.7%, respectively.",5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877884/),%,84.7,80942,DB00233,Aminosalicylic Acid
,2877884,release,The median release of 5-ASA from SASP was 50% and from Pentasa 75%.,5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877884/),%,50,80943,DB00233,Aminosalicylic Acid
,2877884,release,The median release of 5-ASA from SASP was 50% and from Pentasa 75%.,5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877884/),%,75,80944,DB00233,Aminosalicylic Acid
,25861340,C2hr,"Second-line drugs tested were cycloserine in seven patients (mean C2hr, 16.6±10.2 µg/mL; 4 [57%] below expected range); moxifloxacin in five (mean C2hr, 3.2±1.5 µg/mL; 1 [20%] below); capreomycin in five (mean C2hr, 21.5±14.0 µg/mL; 3 [60%] below); para-aminosalicylic acid in five (mean C6hr, 65.0±29.1 µg/mL; all within or above); linezolid in three (mean C2hr, 11.4±4.1 µg/mL, 1 [33%] below); amikacin in two (mean C2hr, 35.3±3.7 µg/mL; 1 [50%] below); ethionamide in one (C2hr, 1.49 µg/mL, within expected).","Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25861340/),[μg] / [ml],16.6,87156,DB00233,Aminosalicylic Acid
,25861340,C2hr,"Second-line drugs tested were cycloserine in seven patients (mean C2hr, 16.6±10.2 µg/mL; 4 [57%] below expected range); moxifloxacin in five (mean C2hr, 3.2±1.5 µg/mL; 1 [20%] below); capreomycin in five (mean C2hr, 21.5±14.0 µg/mL; 3 [60%] below); para-aminosalicylic acid in five (mean C6hr, 65.0±29.1 µg/mL; all within or above); linezolid in three (mean C2hr, 11.4±4.1 µg/mL, 1 [33%] below); amikacin in two (mean C2hr, 35.3±3.7 µg/mL; 1 [50%] below); ethionamide in one (C2hr, 1.49 µg/mL, within expected).","Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25861340/),[μg] / [ml],3.2,87157,DB00233,Aminosalicylic Acid
,25861340,C2hr,"Second-line drugs tested were cycloserine in seven patients (mean C2hr, 16.6±10.2 µg/mL; 4 [57%] below expected range); moxifloxacin in five (mean C2hr, 3.2±1.5 µg/mL; 1 [20%] below); capreomycin in five (mean C2hr, 21.5±14.0 µg/mL; 3 [60%] below); para-aminosalicylic acid in five (mean C6hr, 65.0±29.1 µg/mL; all within or above); linezolid in three (mean C2hr, 11.4±4.1 µg/mL, 1 [33%] below); amikacin in two (mean C2hr, 35.3±3.7 µg/mL; 1 [50%] below); ethionamide in one (C2hr, 1.49 µg/mL, within expected).","Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25861340/),[μg] / [ml],21.5,87158,DB00233,Aminosalicylic Acid
,25861340,C6hr,"Second-line drugs tested were cycloserine in seven patients (mean C2hr, 16.6±10.2 µg/mL; 4 [57%] below expected range); moxifloxacin in five (mean C2hr, 3.2±1.5 µg/mL; 1 [20%] below); capreomycin in five (mean C2hr, 21.5±14.0 µg/mL; 3 [60%] below); para-aminosalicylic acid in five (mean C6hr, 65.0±29.1 µg/mL; all within or above); linezolid in three (mean C2hr, 11.4±4.1 µg/mL, 1 [33%] below); amikacin in two (mean C2hr, 35.3±3.7 µg/mL; 1 [50%] below); ethionamide in one (C2hr, 1.49 µg/mL, within expected).","Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25861340/),[μg] / [ml],65.0,87159,DB00233,Aminosalicylic Acid
,25861340,C2hr,"Second-line drugs tested were cycloserine in seven patients (mean C2hr, 16.6±10.2 µg/mL; 4 [57%] below expected range); moxifloxacin in five (mean C2hr, 3.2±1.5 µg/mL; 1 [20%] below); capreomycin in five (mean C2hr, 21.5±14.0 µg/mL; 3 [60%] below); para-aminosalicylic acid in five (mean C6hr, 65.0±29.1 µg/mL; all within or above); linezolid in three (mean C2hr, 11.4±4.1 µg/mL, 1 [33%] below); amikacin in two (mean C2hr, 35.3±3.7 µg/mL; 1 [50%] below); ethionamide in one (C2hr, 1.49 µg/mL, within expected).","Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25861340/),[μg] / [ml],11.4,87160,DB00233,Aminosalicylic Acid
,25861340,C2hr,"Second-line drugs tested were cycloserine in seven patients (mean C2hr, 16.6±10.2 µg/mL; 4 [57%] below expected range); moxifloxacin in five (mean C2hr, 3.2±1.5 µg/mL; 1 [20%] below); capreomycin in five (mean C2hr, 21.5±14.0 µg/mL; 3 [60%] below); para-aminosalicylic acid in five (mean C6hr, 65.0±29.1 µg/mL; all within or above); linezolid in three (mean C2hr, 11.4±4.1 µg/mL, 1 [33%] below); amikacin in two (mean C2hr, 35.3±3.7 µg/mL; 1 [50%] below); ethionamide in one (C2hr, 1.49 µg/mL, within expected).","Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25861340/),[μg] / [ml],35.3,87161,DB00233,Aminosalicylic Acid
,25861340,C2hr,"Second-line drugs tested were cycloserine in seven patients (mean C2hr, 16.6±10.2 µg/mL; 4 [57%] below expected range); moxifloxacin in five (mean C2hr, 3.2±1.5 µg/mL; 1 [20%] below); capreomycin in five (mean C2hr, 21.5±14.0 µg/mL; 3 [60%] below); para-aminosalicylic acid in five (mean C6hr, 65.0±29.1 µg/mL; all within or above); linezolid in three (mean C2hr, 11.4±4.1 µg/mL, 1 [33%] below); amikacin in two (mean C2hr, 35.3±3.7 µg/mL; 1 [50%] below); ethionamide in one (C2hr, 1.49 µg/mL, within expected).","Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25861340/),[μg] / [ml],1.49,87162,DB00233,Aminosalicylic Acid
,1748043,plasma half-life,"Following intravenous administration, the drug was rapidly eliminated with a plasma half-life of about 40 min, mainly due to rapid metabolism.",Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per os slow-release formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1748043/),min,40,91724,DB00233,Aminosalicylic Acid
,1748043,total recovery,"No parent drug was recovered in feces, and the total recovery following oral administration (30%) was significantly lower than following the intravenous doses (77% and 72%).",Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per os slow-release formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1748043/),%,30,91725,DB00233,Aminosalicylic Acid
,1748043,total recovery,"No parent drug was recovered in feces, and the total recovery following oral administration (30%) was significantly lower than following the intravenous doses (77% and 72%).",Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per os slow-release formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1748043/),%,77,91726,DB00233,Aminosalicylic Acid
,1748043,total recovery,"No parent drug was recovered in feces, and the total recovery following oral administration (30%) was significantly lower than following the intravenous doses (77% and 72%).",Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per os slow-release formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1748043/),%,72,91727,DB00233,Aminosalicylic Acid
,7117789,steady state plasma acetyl-5-aminosalicylic acid concentration,Fourteen healthy volunteers took 1500 mg of 5-aminosalicylic acid per day for 6 days and a steady state plasma acetyl-5-aminosalicylic acid concentration was reached on day 5 (1.1-2.9 microgram/ml).,"5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7117789/),[μg] / [ml],1.1-2.9,93162,DB00233,Aminosalicylic Acid
,21768272,elimination t(½),"After administration, the concentrations of PAS declined rapidly in plasma with an elimination t(½) of 34 min; the metabolite AcPAS was detected in plasma and eliminated with a t(½) of 147 min.",Brain regional pharmacokinetics of p-aminosalicylic acid and its N-acetylated metabolite: effectiveness in chelating brain manganese. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21768272/),min,34,95092,DB00233,Aminosalicylic Acid
,21768272,t(½),"After administration, the concentrations of PAS declined rapidly in plasma with an elimination t(½) of 34 min; the metabolite AcPAS was detected in plasma and eliminated with a t(½) of 147 min.",Brain regional pharmacokinetics of p-aminosalicylic acid and its N-acetylated metabolite: effectiveness in chelating brain manganese. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21768272/),min,147,95093,DB00233,Aminosalicylic Acid
,4039590,elimination half-life (t 1/2),"During treatment with 0.5 g 5-AS tid elimination half-life (t 1/2) ranged from 0.7 to 2.4 h (1.4 +/- 0.6 h, mean +/- SD; n = 6) and mean steady-state plasma levels (Css) of 5-AS and Ac-5-AS averaged 0.7 +/- 0.4 micrograms/ml and 1.2 +/- 0.3 micrograms/ml, respectively.",A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039590/),h,0.7 to 2.4,104650,DB00233,Aminosalicylic Acid
,4039590,elimination half-life (t 1/2),"During treatment with 0.5 g 5-AS tid elimination half-life (t 1/2) ranged from 0.7 to 2.4 h (1.4 +/- 0.6 h, mean +/- SD; n = 6) and mean steady-state plasma levels (Css) of 5-AS and Ac-5-AS averaged 0.7 +/- 0.4 micrograms/ml and 1.2 +/- 0.3 micrograms/ml, respectively.",A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039590/),h,1.4,104651,DB00233,Aminosalicylic Acid
,4039590,steady-state plasma levels (Css),"During treatment with 0.5 g 5-AS tid elimination half-life (t 1/2) ranged from 0.7 to 2.4 h (1.4 +/- 0.6 h, mean +/- SD; n = 6) and mean steady-state plasma levels (Css) of 5-AS and Ac-5-AS averaged 0.7 +/- 0.4 micrograms/ml and 1.2 +/- 0.3 micrograms/ml, respectively.",A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039590/),[μg] / [ml],0.7,104652,DB00233,Aminosalicylic Acid
,4039590,steady-state plasma levels (Css),"During treatment with 0.5 g 5-AS tid elimination half-life (t 1/2) ranged from 0.7 to 2.4 h (1.4 +/- 0.6 h, mean +/- SD; n = 6) and mean steady-state plasma levels (Css) of 5-AS and Ac-5-AS averaged 0.7 +/- 0.4 micrograms/ml and 1.2 +/- 0.3 micrograms/ml, respectively.",A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039590/),[μg] / [ml],1.2,104653,DB00233,Aminosalicylic Acid
,4039590,t 1/2,"Treatment with the smaller dose of 0.25 g 5-AS tid (n = 5) resulted in a shorter t 1/2 (0.6 +/- 0.2 h), lower Css for 5-AS (0.4 +/- 0.2 micrograms/ml) and Ac-5-AS (1.0 +/- 0.2 micrograms/ml).",A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039590/),h,0.6,104654,DB00233,Aminosalicylic Acid
,4039590,Css,"Treatment with the smaller dose of 0.25 g 5-AS tid (n = 5) resulted in a shorter t 1/2 (0.6 +/- 0.2 h), lower Css for 5-AS (0.4 +/- 0.2 micrograms/ml) and Ac-5-AS (1.0 +/- 0.2 micrograms/ml).",A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039590/),[μg] / [ml],0.4,104655,DB00233,Aminosalicylic Acid
,4039590,Css,"Treatment with the smaller dose of 0.25 g 5-AS tid (n = 5) resulted in a shorter t 1/2 (0.6 +/- 0.2 h), lower Css for 5-AS (0.4 +/- 0.2 micrograms/ml) and Ac-5-AS (1.0 +/- 0.2 micrograms/ml).",A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039590/),[μg] / [ml],1.0,104656,DB00233,Aminosalicylic Acid
,4039590,Urinary,"Urinary and fecal recovery of total 5-AS was calculated to 44 +/- 21% and 35 +/- 10%, respectively.",A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039590/),%,44,104657,DB00233,Aminosalicylic Acid
,4039590,f,"Urinary and fecal recovery of total 5-AS was calculated to 44 +/- 21% and 35 +/- 10%, respectively.",A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039590/),%,44,104658,DB00233,Aminosalicylic Acid
,4039590,f,"Urinary and fecal recovery of total 5-AS was calculated to 44 +/- 21% and 35 +/- 10%, respectively.",A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039590/),%,35,104659,DB00233,Aminosalicylic Acid
,8141827,AUC,In none of the pharmacokinetic parameters of 5-ASA characterizing bioavailability (e.g. AUC approximately 6 ug/ml x h; Cmax approximately 1.7 micrograms/ml; tmax approximately 5 h; Cminss approximately 0.5 micrograms/ml; Cavss approximately 0.75 microgram/ml) differences between both forms were observed and the calculated 90% confidence intervals and point estimates indicated bioequivalence.,Steady state disposition of 5-aminosalicyclic acid following oral dosing. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141827/),[ug] / [h·ml],6,115988,DB00233,Aminosalicylic Acid
,8141827,Cmax,In none of the pharmacokinetic parameters of 5-ASA characterizing bioavailability (e.g. AUC approximately 6 ug/ml x h; Cmax approximately 1.7 micrograms/ml; tmax approximately 5 h; Cminss approximately 0.5 micrograms/ml; Cavss approximately 0.75 microgram/ml) differences between both forms were observed and the calculated 90% confidence intervals and point estimates indicated bioequivalence.,Steady state disposition of 5-aminosalicyclic acid following oral dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141827/),[μg] / [ml],1.7,115989,DB00233,Aminosalicylic Acid
,8141827,tmax,In none of the pharmacokinetic parameters of 5-ASA characterizing bioavailability (e.g. AUC approximately 6 ug/ml x h; Cmax approximately 1.7 micrograms/ml; tmax approximately 5 h; Cminss approximately 0.5 micrograms/ml; Cavss approximately 0.75 microgram/ml) differences between both forms were observed and the calculated 90% confidence intervals and point estimates indicated bioequivalence.,Steady state disposition of 5-aminosalicyclic acid following oral dosing. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141827/),h,5,115990,DB00233,Aminosalicylic Acid
,8141827,Cminss,In none of the pharmacokinetic parameters of 5-ASA characterizing bioavailability (e.g. AUC approximately 6 ug/ml x h; Cmax approximately 1.7 micrograms/ml; tmax approximately 5 h; Cminss approximately 0.5 micrograms/ml; Cavss approximately 0.75 microgram/ml) differences between both forms were observed and the calculated 90% confidence intervals and point estimates indicated bioequivalence.,Steady state disposition of 5-aminosalicyclic acid following oral dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141827/),[μg] / [ml],0.5,115991,DB00233,Aminosalicylic Acid
,8141827,Cavss,In none of the pharmacokinetic parameters of 5-ASA characterizing bioavailability (e.g. AUC approximately 6 ug/ml x h; Cmax approximately 1.7 micrograms/ml; tmax approximately 5 h; Cminss approximately 0.5 micrograms/ml; Cavss approximately 0.75 microgram/ml) differences between both forms were observed and the calculated 90% confidence intervals and point estimates indicated bioequivalence.,Steady state disposition of 5-aminosalicyclic acid following oral dosing. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141827/),[μg] / [ml],0.75,115992,DB00233,Aminosalicylic Acid
,8141827,t1/2,Following the delayed absorption 5-ASA was rapidly eliminated (t1/2 = 1.4 +/- 0.5 h).,Steady state disposition of 5-aminosalicyclic acid following oral dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141827/),h,1.4,115993,DB00233,Aminosalicylic Acid
,3203708,elimination half-life,"The study showed that: 1. OLZ had a very short elimination half-life, mean 56 min.",The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203708/),min,56,125197,DB00233,Aminosalicylic Acid
,3203708,serum half-life,Following the i.v. dose the serum half-life of the O-sulphate was estimated to be 7 days.,The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203708/),d,7,125198,DB00233,Aminosalicylic Acid
,25963985,time above the MIC,The time above the MIC of 1 mg/liter was significantly different between the two regimens but not influenced by the NAT1 or NAT2 genotypes.,N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963985/),[mg] / [l],1,129242,DB00233,Aminosalicylic Acid
,25963985,MIC,Four grams of GSR-PAS twice daily but not 8 g once daily ensured concentrations exceeding the MIC (1 mg/liter) throughout the dosing interval; PAS intolerance was not related to maximum PAS concentrations over the doses studied and was not more frequent after once-daily dosing.,N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963985/),[mg] / [l],1,129243,DB00233,Aminosalicylic Acid
,2565380,steady state plasma level,Range of variable steady state plasma level of 5-ASA was 0.1-5 mg/L and of its acetyl-metabolite (Ac-5-ASA) was 1-8 mg/L.,Oral 5-aminosalicyclic acid in children with colonic chronic inflammatory bowel disease: clinical and pharmacokinetic experience. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565380/),[mg] / [l],0.1-5,134318,DB00233,Aminosalicylic Acid
,2565380,steady state plasma level,Range of variable steady state plasma level of 5-ASA was 0.1-5 mg/L and of its acetyl-metabolite (Ac-5-ASA) was 1-8 mg/L.,Oral 5-aminosalicyclic acid in children with colonic chronic inflammatory bowel disease: clinical and pharmacokinetic experience. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565380/),[mg] / [l],1-8,134319,DB00233,Aminosalicylic Acid
,2059673,AUC,"Within and between subject variability estimates for AUC of ac-5-ASA were 24 per cent and 46 per cent, respectively.",Relative bioavailability of olsalazine from tablets and capsules: a drug targeted for local effect in the colon. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2059673/),%,24,134430,DB00233,Aminosalicylic Acid
,2059673,AUC,"Within and between subject variability estimates for AUC of ac-5-ASA were 24 per cent and 46 per cent, respectively.",Relative bioavailability of olsalazine from tablets and capsules: a drug targeted for local effect in the colon. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2059673/),%,46,134431,DB00233,Aminosalicylic Acid
,2864155,elimination half-life,Sulphasalazine itself is poorly absorbed (3 to 12%) and its elimination half-life of about 5 to 10 hours is probably affected by the absorption process.,"Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),h,5 to 10,139123,DB00233,Aminosalicylic Acid
,2864155,elimination half-life,"Depending on the genetic phenotype, the elimination half-life and apparent oral clearance of sulphapyridine are approximately 14 hours and 40 ml/min (slow acetylators) or 6 hours and 150 ml/min (fast acetylators), respectively.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),h,14,139124,DB00233,Aminosalicylic Acid
,2864155,elimination half-life,"Depending on the genetic phenotype, the elimination half-life and apparent oral clearance of sulphapyridine are approximately 14 hours and 40 ml/min (slow acetylators) or 6 hours and 150 ml/min (fast acetylators), respectively.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),h,6,139125,DB00233,Aminosalicylic Acid
,2864155,apparent oral clearance,"Depending on the genetic phenotype, the elimination half-life and apparent oral clearance of sulphapyridine are approximately 14 hours and 40 ml/min (slow acetylators) or 6 hours and 150 ml/min (fast acetylators), respectively.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),[ml] / [min],40,139126,DB00233,Aminosalicylic Acid
,2864155,apparent oral clearance,"Depending on the genetic phenotype, the elimination half-life and apparent oral clearance of sulphapyridine are approximately 14 hours and 40 ml/min (slow acetylators) or 6 hours and 150 ml/min (fast acetylators), respectively.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),[ml] / [min],150,139127,DB00233,Aminosalicylic Acid
,2864155,elimination half-life,"While the elimination half-life of 5-ASA is short (0.5 to 1.5 h), its major acetylated metabolite (which may be active) exhibits a half-life of 5 to 10 hours.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),h,0.5 to 1.5,139128,DB00233,Aminosalicylic Acid
,2864155,half-life,"While the elimination half-life of 5-ASA is short (0.5 to 1.5 h), its major acetylated metabolite (which may be active) exhibits a half-life of 5 to 10 hours.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),h,5 to 10,139129,DB00233,Aminosalicylic Acid
less,2864155,steady-state plasma concentrations,"During therapy with sulphasalazine or 5-ASA, steady-state plasma concentrations of 5-ASA are relatively low (less than or equal to 2 micrograms/ml); thus its mode of action appears to be topically rather than systemically.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),[μg] / [ml],2,139130,DB00233,Aminosalicylic Acid
,10051275,serum concentrations,"In six patients, twice-daily dosing produced median serum concentrations at 4, 8, and 12 h post-dose of 25.8, 23.2, and 16.4 microgram/ml.",Once-daily and twice-daily dosing of p-aminosalicylic acid granules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051275/),[μg] / [ml],25.8,142346,DB00233,Aminosalicylic Acid
,10051275,serum concentrations,"In six patients, twice-daily dosing produced median serum concentrations at 4, 8, and 12 h post-dose of 25.8, 23.2, and 16.4 microgram/ml.",Once-daily and twice-daily dosing of p-aminosalicylic acid granules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051275/),[μg] / [ml],23.2,142347,DB00233,Aminosalicylic Acid
,10051275,serum concentrations,"In six patients, twice-daily dosing produced median serum concentrations at 4, 8, and 12 h post-dose of 25.8, 23.2, and 16.4 microgram/ml.",Once-daily and twice-daily dosing of p-aminosalicylic acid granules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051275/),[μg] / [ml],16.4,142348,DB00233,Aminosalicylic Acid
,10051275,serum concentrations,"In six patients, once-daily dosing produced median serum concentrations at 6, 12, and 24 h post-dose of 23.4, 3.7, and 0 microgram/ml.",Once-daily and twice-daily dosing of p-aminosalicylic acid granules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051275/),[μg] / [ml],23.4,142349,DB00233,Aminosalicylic Acid
,10051275,serum concentrations,"In six patients, once-daily dosing produced median serum concentrations at 6, 12, and 24 h post-dose of 23.4, 3.7, and 0 microgram/ml.",Once-daily and twice-daily dosing of p-aminosalicylic acid granules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051275/),[μg] / [ml],3.7,142350,DB00233,Aminosalicylic Acid
,10051275,serum concentrations,"In six patients, once-daily dosing produced median serum concentrations at 6, 12, and 24 h post-dose of 23.4, 3.7, and 0 microgram/ml.",Once-daily and twice-daily dosing of p-aminosalicylic acid granules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051275/),[μg] / [ml],0,142351,DB00233,Aminosalicylic Acid
,10051275,serum concentrations,"In 40 patients, twice-daily dosing produced median serum concentrations at 4 to 8 and 9 to 12 h post-dose of 24.8 and 20.6 microgram/ml.",Once-daily and twice-daily dosing of p-aminosalicylic acid granules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051275/),[μg] / [ml],24.8,142352,DB00233,Aminosalicylic Acid
,10051275,serum concentrations,"In 40 patients, twice-daily dosing produced median serum concentrations at 4 to 8 and 9 to 12 h post-dose of 24.8 and 20.6 microgram/ml.",Once-daily and twice-daily dosing of p-aminosalicylic acid granules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051275/),[μg] / [ml],20.6,142353,DB00233,Aminosalicylic Acid
,2129640,urinary excretion,"However, we found a smaller urinary excretion of 5-ASA and Ac-5-ASA (5.2% vs Claversal 27.9% and Pentasa 23.0%, median values of ingested daily dose) and a lower concentration of Ac-5-ASA in the ileostomy effluents after Asacol treatment (0.8 mmol/L, median value) which indicates a more distal release from this preparation compared with Claversal (2.4 mmol/L, median value) and Pentasa (5.5 mmol/L, median value).",Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2129640/),%,5.2,144701,DB00233,Aminosalicylic Acid
,2129640,urinary excretion,"However, we found a smaller urinary excretion of 5-ASA and Ac-5-ASA (5.2% vs Claversal 27.9% and Pentasa 23.0%, median values of ingested daily dose) and a lower concentration of Ac-5-ASA in the ileostomy effluents after Asacol treatment (0.8 mmol/L, median value) which indicates a more distal release from this preparation compared with Claversal (2.4 mmol/L, median value) and Pentasa (5.5 mmol/L, median value).",Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2129640/),%,27.9,144702,DB00233,Aminosalicylic Acid
,2129640,urinary excretion,"However, we found a smaller urinary excretion of 5-ASA and Ac-5-ASA (5.2% vs Claversal 27.9% and Pentasa 23.0%, median values of ingested daily dose) and a lower concentration of Ac-5-ASA in the ileostomy effluents after Asacol treatment (0.8 mmol/L, median value) which indicates a more distal release from this preparation compared with Claversal (2.4 mmol/L, median value) and Pentasa (5.5 mmol/L, median value).",Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2129640/),%,23.0,144703,DB00233,Aminosalicylic Acid
,2129640,concentration,"However, we found a smaller urinary excretion of 5-ASA and Ac-5-ASA (5.2% vs Claversal 27.9% and Pentasa 23.0%, median values of ingested daily dose) and a lower concentration of Ac-5-ASA in the ileostomy effluents after Asacol treatment (0.8 mmol/L, median value) which indicates a more distal release from this preparation compared with Claversal (2.4 mmol/L, median value) and Pentasa (5.5 mmol/L, median value).",Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2129640/),[mM] / [l],0.8,144704,DB00233,Aminosalicylic Acid
,2129640,release,"However, we found a smaller urinary excretion of 5-ASA and Ac-5-ASA (5.2% vs Claversal 27.9% and Pentasa 23.0%, median values of ingested daily dose) and a lower concentration of Ac-5-ASA in the ileostomy effluents after Asacol treatment (0.8 mmol/L, median value) which indicates a more distal release from this preparation compared with Claversal (2.4 mmol/L, median value) and Pentasa (5.5 mmol/L, median value).",Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2129640/),[mM] / [l],2.4,144705,DB00233,Aminosalicylic Acid
,2129640,release,"However, we found a smaller urinary excretion of 5-ASA and Ac-5-ASA (5.2% vs Claversal 27.9% and Pentasa 23.0%, median values of ingested daily dose) and a lower concentration of Ac-5-ASA in the ileostomy effluents after Asacol treatment (0.8 mmol/L, median value) which indicates a more distal release from this preparation compared with Claversal (2.4 mmol/L, median value) and Pentasa (5.5 mmol/L, median value).",Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2129640/),mm,5.5,144706,DB00233,Aminosalicylic Acid
,2129640,urinary excretion,"This can be explained by a larger systemic absorption of 5-ASA from Claversal, and accordingly Claversal treatment resulted in the largest urinary excretion of 5-ASA and Ac-5-ASA (43.7% vs Asacol 35.6% and Pentasa 31.6%, median values of ingested daily dose).",Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2129640/),%,43.7,144707,DB00233,Aminosalicylic Acid
,2129640,urinary excretion,"This can be explained by a larger systemic absorption of 5-ASA from Claversal, and accordingly Claversal treatment resulted in the largest urinary excretion of 5-ASA and Ac-5-ASA (43.7% vs Asacol 35.6% and Pentasa 31.6%, median values of ingested daily dose).",Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2129640/),%,35.6,144708,DB00233,Aminosalicylic Acid
,2129640,urinary excretion,"This can be explained by a larger systemic absorption of 5-ASA from Claversal, and accordingly Claversal treatment resulted in the largest urinary excretion of 5-ASA and Ac-5-ASA (43.7% vs Asacol 35.6% and Pentasa 31.6%, median values of ingested daily dose).",Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2129640/),%,31.6,144709,DB00233,Aminosalicylic Acid
,10531163,blood flow rate,"Open-label, pharmacokinetic study Outpatient long-term hemodialysis unit Eight long-term hemodialysis patients Interventions: Single oral doses of CS, 500 mg, ETA, 500 mg, PAS, 4,000 mg, and CFZ, 200 mg, were given 2 h (4 h for PAS) prior to hemodialysis (median blood flow rate, 400 mL/min; median dialysate flow rate, 600 mL/min; median hemodialysis time, 3.5 h).","The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10531163/),[ml] / [min],400,146001,DB00233,Aminosalicylic Acid
,10531163,dial,"Open-label, pharmacokinetic study Outpatient long-term hemodialysis unit Eight long-term hemodialysis patients Interventions: Single oral doses of CS, 500 mg, ETA, 500 mg, PAS, 4,000 mg, and CFZ, 200 mg, were given 2 h (4 h for PAS) prior to hemodialysis (median blood flow rate, 400 mL/min; median dialysate flow rate, 600 mL/min; median hemodialysis time, 3.5 h).","The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10531163/),[ml] / [min],600,146002,DB00233,Aminosalicylic Acid
,10531163,flow rate,"Open-label, pharmacokinetic study Outpatient long-term hemodialysis unit Eight long-term hemodialysis patients Interventions: Single oral doses of CS, 500 mg, ETA, 500 mg, PAS, 4,000 mg, and CFZ, 200 mg, were given 2 h (4 h for PAS) prior to hemodialysis (median blood flow rate, 400 mL/min; median dialysate flow rate, 600 mL/min; median hemodialysis time, 3.5 h).","The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10531163/),[ml] / [min],600,146003,DB00233,Aminosalicylic Acid
,10531163,recoveries,"Median recoveries of drug in dialysate were 56% (CS), 2.1% (ETA), 6.3% (PAS parent compound), and 0% (CFZ) of the doses administered.","The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10531163/),%,56,146004,DB00233,Aminosalicylic Acid
,10531163,recoveries,"Median recoveries of drug in dialysate were 56% (CS), 2.1% (ETA), 6.3% (PAS parent compound), and 0% (CFZ) of the doses administered.","The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10531163/),%,2.1,146005,DB00233,Aminosalicylic Acid
,10531163,recoveries,"Median recoveries of drug in dialysate were 56% (CS), 2.1% (ETA), 6.3% (PAS parent compound), and 0% (CFZ) of the doses administered.","The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10531163/),%,6.3,146006,DB00233,Aminosalicylic Acid
,10531163,recoveries,"Median recoveries of drug in dialysate were 56% (CS), 2.1% (ETA), 6.3% (PAS parent compound), and 0% (CFZ) of the doses administered.","The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10531163/),%,0,146007,DB00233,Aminosalicylic Acid
,10531163,clearances,"Median hemodialysis clearances calculated by dividing the amount recovered in dialysate by the serum area under the curve during dialysis were 189 (CS), 58 (ETA), 206 (PAS), and 0 (CFZ) mL/min.","The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10531163/),[ml] / [min],189,146008,DB00233,Aminosalicylic Acid
,10531163,clearances,"Median hemodialysis clearances calculated by dividing the amount recovered in dialysate by the serum area under the curve during dialysis were 189 (CS), 58 (ETA), 206 (PAS), and 0 (CFZ) mL/min.","The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10531163/),[ml] / [min],58,146009,DB00233,Aminosalicylic Acid
,10531163,clearances,"Median hemodialysis clearances calculated by dividing the amount recovered in dialysate by the serum area under the curve during dialysis were 189 (CS), 58 (ETA), 206 (PAS), and 0 (CFZ) mL/min.","The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10531163/),[ml] / [min],206,146010,DB00233,Aminosalicylic Acid
,10531163,clearances,"Median hemodialysis clearances calculated by dividing the amount recovered in dialysate by the serum area under the curve during dialysis were 189 (CS), 58 (ETA), 206 (PAS), and 0 (CFZ) mL/min.","The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10531163/),[ml] / [min],0,146011,DB00233,Aminosalicylic Acid
,23174991,Cmax,"The mean Cmax in children receiving PAS 75 mg/kg and 150 mg/kg and adults receiving 4 g was 45.40, 56.49 and 51.3 µg/ml, respectively (p = 0.614); the AUC0-12 was 233.3, 277.9 and 368.0 µg/h/ml (p = 0.587).",Para-aminosalicylic acid plasma concentrations in children in comparison with adults after receiving a granular slow-release preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23174991/),[μg] / [ml],45.40,158296,DB00233,Aminosalicylic Acid
,23174991,Cmax,"The mean Cmax in children receiving PAS 75 mg/kg and 150 mg/kg and adults receiving 4 g was 45.40, 56.49 and 51.3 µg/ml, respectively (p = 0.614); the AUC0-12 was 233.3, 277.9 and 368.0 µg/h/ml (p = 0.587).",Para-aminosalicylic acid plasma concentrations in children in comparison with adults after receiving a granular slow-release preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23174991/),[μg] / [ml],56.49,158297,DB00233,Aminosalicylic Acid
,23174991,Cmax,"The mean Cmax in children receiving PAS 75 mg/kg and 150 mg/kg and adults receiving 4 g was 45.40, 56.49 and 51.3 µg/ml, respectively (p = 0.614); the AUC0-12 was 233.3, 277.9 and 368.0 µg/h/ml (p = 0.587).",Para-aminosalicylic acid plasma concentrations in children in comparison with adults after receiving a granular slow-release preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23174991/),[μg] / [ml],51.3,158298,DB00233,Aminosalicylic Acid
,23174991,AUC0-12,"The mean Cmax in children receiving PAS 75 mg/kg and 150 mg/kg and adults receiving 4 g was 45.40, 56.49 and 51.3 µg/ml, respectively (p = 0.614); the AUC0-12 was 233.3, 277.9 and 368.0 µg/h/ml (p = 0.587).",Para-aminosalicylic acid plasma concentrations in children in comparison with adults after receiving a granular slow-release preparation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23174991/),[μg] / [h·ml],233.3,158299,DB00233,Aminosalicylic Acid
,23174991,AUC0-12,"The mean Cmax in children receiving PAS 75 mg/kg and 150 mg/kg and adults receiving 4 g was 45.40, 56.49 and 51.3 µg/ml, respectively (p = 0.614); the AUC0-12 was 233.3, 277.9 and 368.0 µg/h/ml (p = 0.587).",Para-aminosalicylic acid plasma concentrations in children in comparison with adults after receiving a granular slow-release preparation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23174991/),[μg] / [h·ml],277.9,158300,DB00233,Aminosalicylic Acid
,23174991,AUC0-12,"The mean Cmax in children receiving PAS 75 mg/kg and 150 mg/kg and adults receiving 4 g was 45.40, 56.49 and 51.3 µg/ml, respectively (p = 0.614); the AUC0-12 was 233.3, 277.9 and 368.0 µg/h/ml (p = 0.587).",Para-aminosalicylic acid plasma concentrations in children in comparison with adults after receiving a granular slow-release preparation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23174991/),[μg] / [h·ml],368.0,158301,DB00233,Aminosalicylic Acid
,16393291,relative percentage of,The relative percentage of 5-ASA absorption was more pronounced in the ascending colon (41 +/- 27.4%) than the ileo-caecal region (6.6 +/- 9.2%).,5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16393291/),%,41,165593,DB00233,Aminosalicylic Acid
,16393291,relative percentage of,The relative percentage of 5-ASA absorption was more pronounced in the ascending colon (41 +/- 27.4%) than the ileo-caecal region (6.6 +/- 9.2%).,5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16393291/),%,6.6,165594,DB00233,Aminosalicylic Acid
,15525560,oral clearance,"From the population analysis (one-compartment model), the mean oral clearance was 76.7 l/h (CV=74.2%) and mean apparent volume of distribution was 1470 l (CV=36.3%).","Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15525560/),[l] / [h],76.7,170952,DB00233,Aminosalicylic Acid
,15525560,apparent volume of distribution,"From the population analysis (one-compartment model), the mean oral clearance was 76.7 l/h (CV=74.2%) and mean apparent volume of distribution was 1470 l (CV=36.3%).","Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15525560/),l,1470,170953,DB00233,Aminosalicylic Acid
,15525560,first-order absorption rate constant,The first-order absorption rate constant ranged from 0.716 to 1.33 h(-1) (pooled CV=61.7%).,"Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15525560/),1/[h],0.716 to 1.33,170954,DB00233,Aminosalicylic Acid
,15525560,bioavailability,"Estimates of bioavailability compared to fasting administration were 145% (90% CI, 107-183%) for administration with high fat food, 82.0% (63.2-101%) for administration with orange juice, and 78.5% (55.1-102%) for administration with antacid.","Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15525560/),%,145,170955,DB00233,Aminosalicylic Acid
,15525560,bioavailability,"Estimates of bioavailability compared to fasting administration were 145% (90% CI, 107-183%) for administration with high fat food, 82.0% (63.2-101%) for administration with orange juice, and 78.5% (55.1-102%) for administration with antacid.","Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15525560/),%,82.0,170956,DB00233,Aminosalicylic Acid
,15525560,bioavailability,"Estimates of bioavailability compared to fasting administration were 145% (90% CI, 107-183%) for administration with high fat food, 82.0% (63.2-101%) for administration with orange juice, and 78.5% (55.1-102%) for administration with antacid.","Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15525560/),%,78.5,170957,DB00233,Aminosalicylic Acid
less,10976656,maximal plasma concentrations,"Most studies report maximal plasma concentrations of less than 1 mg/L after oral administration of slow release mesalazine, much lower than those observed after uncoated mesalazine but generally higher than after azo-bound drugs such as sulfasalazine.",Clinical pharmacokinetics of slow release mesalazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976656/),[mg] / [l],1,175041,DB00233,Aminosalicylic Acid
,10976656,steady-state concentrations,Mean steady-state concentrations of 25.7+/-2.2 microg/kg wet weight are found in ileocolonic biopsy specimens from patients with irritable bowel syndrome treated for 1 week with slow release mesalazine 1.5 g/day.,Clinical pharmacokinetics of slow release mesalazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976656/),[μg] / [kg·weight·wet],25.7,175042,DB00233,Aminosalicylic Acid
,26606108,m,The multiple reaction monitoring (MRM) mode of the negative ion was performed and the transitions of m/z 208.1→107.0 and m/z 211.1→110.1 were used to measure the derivative of mesalazine and mesalazine-d3.,"Determination of mesalazine, a low bioavailability olsalazine metabolite in human plasma by UHPLC-MS/MS: Application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26606108/),,208.1,177631,DB00233,Aminosalicylic Acid
,26606108,Nominal retention times,"Nominal retention times of mesalazine and IS were 3.08 and 3.07min, respectively.","Determination of mesalazine, a low bioavailability olsalazine metabolite in human plasma by UHPLC-MS/MS: Application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26606108/),min,3.08,177632,DB00233,Aminosalicylic Acid
,26606108,Nominal retention times,"Nominal retention times of mesalazine and IS were 3.08 and 3.07min, respectively.","Determination of mesalazine, a low bioavailability olsalazine metabolite in human plasma by UHPLC-MS/MS: Application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26606108/),min,3.07,177633,DB00233,Aminosalicylic Acid
,26606108,Absolute recovery,Absolute recovery was found to be between 82-95% for analyte and about 78% for IS.,"Determination of mesalazine, a low bioavailability olsalazine metabolite in human plasma by UHPLC-MS/MS: Application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26606108/),%,82-95,177634,DB00233,Aminosalicylic Acid
,26606108,Absolute recovery,Absolute recovery was found to be between 82-95% for analyte and about 78% for IS.,"Determination of mesalazine, a low bioavailability olsalazine metabolite in human plasma by UHPLC-MS/MS: Application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26606108/),%,78,177635,DB00233,Aminosalicylic Acid
,12269969,overall response,"The overall response, using a minimum decrease of 70 in the Crohn's disease activity index, was 41-47% for the evaluable group, at weeks 8 and 12.",Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12269969/),%,41-47,179281,DB00233,Aminosalicylic Acid
,12269969,partial thromboplastin time prolongation,"The 2-4-h transient post-infusion partial thromboplastin time prolongation values, a class effect of phosphorothioate oligonucleotides, were 18, 21 and 23 s for 250, 300 and 350 mg, respectively.",Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12269969/),s,18,179282,DB00233,Aminosalicylic Acid
,12269969,partial thromboplastin time prolongation,"The 2-4-h transient post-infusion partial thromboplastin time prolongation values, a class effect of phosphorothioate oligonucleotides, were 18, 21 and 23 s for 250, 300 and 350 mg, respectively.",Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12269969/),s,21,179283,DB00233,Aminosalicylic Acid
,12269969,partial thromboplastin time prolongation,"The 2-4-h transient post-infusion partial thromboplastin time prolongation values, a class effect of phosphorothioate oligonucleotides, were 18, 21 and 23 s for 250, 300 and 350 mg, respectively.",Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12269969/),s,23,179284,DB00233,Aminosalicylic Acid
,7853151,rectal absorption,The rectal absorption of RFP from the suppositories containing no PAS-Na (control suppositories) was significantly lower compared to oral administration of it (26%) in human subjects.,[Enhancement of rectal absorption of rifampicin by sodium para-aminosalicylate dihydrate in human subjects]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853151/),%,26,190489,DB00233,Aminosalicylic Acid
greater,7904547,elimination half-lives,Both drugs have reported elimination half-lives of greater than 1 month.,Clinical pharmacokinetics of slow-acting antirheumatic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7904547/),month,1,193639,DB00233,Aminosalicylic Acid
,11853180,maximum concentration (Cmax),"When the SASP suppository was administered, the maximum concentration (Cmax) of SASP and Ac-5-ASA was 2.5+/-0.4 and 0.5+/-0.2 microM and the time to Cmax (Tmax) was 5 and 12 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),μM,2.5,194755,DB00233,Aminosalicylic Acid
,11853180,maximum concentration (Cmax),"When the SASP suppository was administered, the maximum concentration (Cmax) of SASP and Ac-5-ASA was 2.5+/-0.4 and 0.5+/-0.2 microM and the time to Cmax (Tmax) was 5 and 12 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),μM,0.5,194756,DB00233,Aminosalicylic Acid
,11853180,time to Cmax (Tmax),"When the SASP suppository was administered, the maximum concentration (Cmax) of SASP and Ac-5-ASA was 2.5+/-0.4 and 0.5+/-0.2 microM and the time to Cmax (Tmax) was 5 and 12 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),h,5,194757,DB00233,Aminosalicylic Acid
,11853180,time to Cmax (Tmax),"When the SASP suppository was administered, the maximum concentration (Cmax) of SASP and Ac-5-ASA was 2.5+/-0.4 and 0.5+/-0.2 microM and the time to Cmax (Tmax) was 5 and 12 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),h,12,194758,DB00233,Aminosalicylic Acid
,11853180,Cmax,"When the 5-ASA enema was administered, Cmax and Tmax values of 5-ASA and Ac-5-ASA were 5.8+/-2.0 and 13.3+/-3.6 microM and 1 and 7 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),μM,5.8,194759,DB00233,Aminosalicylic Acid
,11853180,Tmax,"When the 5-ASA enema was administered, Cmax and Tmax values of 5-ASA and Ac-5-ASA were 5.8+/-2.0 and 13.3+/-3.6 microM and 1 and 7 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),μM,13.3,194760,DB00233,Aminosalicylic Acid
,11853180,Tmax,"When the 5-ASA enema was administered, Cmax and Tmax values of 5-ASA and Ac-5-ASA were 5.8+/-2.0 and 13.3+/-3.6 microM and 1 and 7 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),h,1,194761,DB00233,Aminosalicylic Acid
,11853180,Tmax,"When the 5-ASA enema was administered, Cmax and Tmax values of 5-ASA and Ac-5-ASA were 5.8+/-2.0 and 13.3+/-3.6 microM and 1 and 7 h, respectively.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),h,7,194762,DB00233,Aminosalicylic Acid
,11853180,area under the serum concentration-time curve (AUC),"The area under the serum concentration-time curve (AUC) of SASP was 27.4+/-4.8 microM x h, a finding similar to that of 5-ASA after the administration of the 5-ASA enema (29.4+/-11.1 microM x h).",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),h·μM,27.4,194763,DB00233,Aminosalicylic Acid
,11853180,area under the serum concentration-time curve (AUC),"The area under the serum concentration-time curve (AUC) of SASP was 27.4+/-4.8 microM x h, a finding similar to that of 5-ASA after the administration of the 5-ASA enema (29.4+/-11.1 microM x h).",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),h·μM,29.4,194764,DB00233,Aminosalicylic Acid
,11853180,percentage of urinary recovery,The percentage of urinary recovery of SASP 24 h after administration of the SASP suppository was approximately 0.2%.,Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),%,0.2,194765,DB00233,Aminosalicylic Acid
more,11853180,urinary recovery,"On the other hand, approximately 0.3% of 5-ASA was recovered in the urine in unchanged form after the administration of the 5-ASA enema, whereas the urinary recovery of Ac-5-ASA was more than 10%.",Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853180/),%,10,194766,DB00233,Aminosalicylic Acid
,2369807,elimination half-life,"The elimination half-life of 5-ASA was 51.9 minutes, whereas the acetyl 5-ASA half-life could not be determined.",Effect of food coadministration on 5-aminosalicylic acid oral suspension bioavailability. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369807/),min,51.9,195222,DB00233,Aminosalicylic Acid
,2369807,systemic relative bioavailability,"Food coadministration reduced 5-ASA and acetyl 5-ASA systemic relative bioavailability to 44% and 76%, respectively, compared with the fasting treatment.",Effect of food coadministration on 5-aminosalicylic acid oral suspension bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369807/),%,44,195223,DB00233,Aminosalicylic Acid
,2369807,systemic relative bioavailability,"Food coadministration reduced 5-ASA and acetyl 5-ASA systemic relative bioavailability to 44% and 76%, respectively, compared with the fasting treatment.",Effect of food coadministration on 5-aminosalicylic acid oral suspension bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369807/),%,76,195224,DB00233,Aminosalicylic Acid
,28408267,absorption rate constant,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),1/[h],0.305,195737,DB00233,Aminosalicylic Acid
,28408267,apparent clearance,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),[l] / [h],9.37,195738,DB00233,Aminosalicylic Acid
,28408267,apparent clearance,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),1/[h],0.135,195739,DB00233,Aminosalicylic Acid
,28408267,apparent clearance,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),1/[h],0.510,195740,DB00233,Aminosalicylic Acid
,28408267,apparent clearance,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),[l] / [h],30.8,195741,DB00233,Aminosalicylic Acid
,28408267,apparent clearance,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),1/[h],1.67,195742,DB00233,Aminosalicylic Acid
,28408267,apparent clearance,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),[l] / [h],3.75,195743,DB00233,Aminosalicylic Acid
,28408267,apparent volume of distribution,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),l,56.7,195744,DB00233,Aminosalicylic Acid
,28408267,apparent volume of distribution,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),l,79.4,195745,DB00233,Aminosalicylic Acid
,28408267,apparent volume of distribution,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),1/[h],1.67,195746,DB00233,Aminosalicylic Acid
,28408267,apparent volume of distribution,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),[l] / [h],3.75,195747,DB00233,Aminosalicylic Acid
,28408267,apparent volume of distribution,"The respective absorption rate constant, apparent clearance and apparent volume of distribution values were as follows: 0.305/h, 9.37 L/h and 56.7 L for moxifloxacin; 0.135/h, 1.38 L/h and 10.5 L for cycloserine; 0.510/h, 30.8 L/h and 79.4 L for PAS; and 1.67/h, 3.75 L/h and 15.2 L for kanamycin.","Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28408267/),l,15.2,195748,DB00233,Aminosalicylic Acid
,747,lambdamax,The violet colored product of the Bratton-Marshall reaction has a lambdamax of 560 nm and conforms to Beer's law over the concentration range of 0-70 umg/ml.,Colorimetric determination of 5-aminosalicylic acid and its N-acetylated metabolite on urine and feces. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/747/),nm,560,198450,DB00233,Aminosalicylic Acid
,747,recoveries,"Average recoveries (+/- S.D., N = 6) OF 5-ASA added to rat and human urine and rat fecal homogenates were 91.6 +/- 4.9%, 102 +/- 6.0%, and 71.0 +/- 4.8%, respectively.",Colorimetric determination of 5-aminosalicylic acid and its N-acetylated metabolite on urine and feces. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/747/),%,91.6,198451,DB00233,Aminosalicylic Acid
,747,recoveries,"Average recoveries (+/- S.D., N = 6) OF 5-ASA added to rat and human urine and rat fecal homogenates were 91.6 +/- 4.9%, 102 +/- 6.0%, and 71.0 +/- 4.8%, respectively.",Colorimetric determination of 5-aminosalicylic acid and its N-acetylated metabolite on urine and feces. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/747/),%,102,198452,DB00233,Aminosalicylic Acid
,747,recoveries,"Average recoveries (+/- S.D., N = 6) OF 5-ASA added to rat and human urine and rat fecal homogenates were 91.6 +/- 4.9%, 102 +/- 6.0%, and 71.0 +/- 4.8%, respectively.",Colorimetric determination of 5-aminosalicylic acid and its N-acetylated metabolite on urine and feces. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/747/),%,71.0,198453,DB00233,Aminosalicylic Acid
,11718495,time to maximum concentration,The high-fat meal significantly (p<0.0001) delayed time to maximum concentration by 4.7 times compared with that of the reference (1.1 hr).,"Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11718495/),h,1.1,203416,DB00233,Aminosalicylic Acid
,2518847,urinary recovery,Median urinary recovery values were 21.7% for Salazopyrin and 35.5% for Mesasal (fasting) (P less than 0.01).,Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2518847/),%,21.7,203986,DB00233,Aminosalicylic Acid
,2518847,urinary recovery,Median urinary recovery values were 21.7% for Salazopyrin and 35.5% for Mesasal (fasting) (P less than 0.01).,Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2518847/),%,35.5,203987,DB00233,Aminosalicylic Acid
,2518847,total faecal recovery,"The total faecal recovery values were 38.3 and 26.5%, respectively (NS).",Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2518847/),%,38.3,203988,DB00233,Aminosalicylic Acid
,2518847,total faecal recovery,"The total faecal recovery values were 38.3 and 26.5%, respectively (NS).",Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2518847/),%,26.5,203989,DB00233,Aminosalicylic Acid
,2518847,urinary recovery,Suppository administration of 5-ASA resulted in a low median urinary recovery of 10.8%.,Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2518847/),%,10.8,203990,DB00233,Aminosalicylic Acid
,1853156,peak plasma concentration,"The median peak plasma concentration of 5-ASA was 0.92 (range, 0.59-1.87) micrograms/ml at a median of 11 h after administration, and of Ac-5-ASA 1.62 (range, 1.03-4.36) micrograms/ml at a median of 12 h after administration.",Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1853156/),[μg] / [ml],0.92,211865,DB00233,Aminosalicylic Acid
,1853156,peak plasma concentration,"The median peak plasma concentration of 5-ASA was 0.92 (range, 0.59-1.87) micrograms/ml at a median of 11 h after administration, and of Ac-5-ASA 1.62 (range, 1.03-4.36) micrograms/ml at a median of 12 h after administration.",Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1853156/),[μg] / [ml],1.62,211866,DB00233,Aminosalicylic Acid
,1853156,plasma concentration,"At 24 h after administration the median plasma concentration for 5-ASA was 0.12 (range, 0-0.77) micrograms/ml and for Ac-5-ASA 0.36 (range, 0.01-1.6) micrograms/ml.",Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1853156/),[μg] / [ml],0.12,211867,DB00233,Aminosalicylic Acid
,1853156,plasma concentration,"At 24 h after administration the median plasma concentration for 5-ASA was 0.12 (range, 0-0.77) micrograms/ml and for Ac-5-ASA 0.36 (range, 0.01-1.6) micrograms/ml.",Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1853156/),[μg] / [ml],0.36,211868,DB00233,Aminosalicylic Acid
,1853156,urinary recovery,"Median urinary recovery during 45 h was 12.6% (range, 5.6-22.2%), indicating a low absorption at steady-state conditions.",Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1853156/),%,12.6,211869,DB00233,Aminosalicylic Acid
,6669934,peak serum concentration,The ADS absorption gave a mean peak serum concentration of 2.1 (SD +/- 0.7) microgram/ml.,Absorption and excretion of azodisal sodium and its metabolites in man after rectal administration of a single 2-g dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6669934/),[μg] / [ml],2.1,220791,DB00233,Aminosalicylic Acid
,6669934,urinary excretion,The urinary excretion of ADS was 0.8% of the given dose.,Absorption and excretion of azodisal sodium and its metabolites in man after rectal administration of a single 2-g dose. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6669934/),%,0.8,220792,DB00233,Aminosalicylic Acid
,6669934,urinary excretion,The mean 24-h urinary excretion of these two metabolites was only 2.7% of the given dose.,Absorption and excretion of azodisal sodium and its metabolites in man after rectal administration of a single 2-g dose. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6669934/),%,2.7,220793,DB00233,Aminosalicylic Acid
,32671846,urinary excretion,"Mean urinary excretion of 5-ASA plus N-Ac-5-ASA was comparable between treatments (dose A 21.3%, dose B 20.2%, dose C 17.9%).","Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32671846/),%,21.3,222790,DB00233,Aminosalicylic Acid
,32671846,urinary excretion,"Mean urinary excretion of 5-ASA plus N-Ac-5-ASA was comparable between treatments (dose A 21.3%, dose B 20.2%, dose C 17.9%).","Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32671846/),%,20.2,222791,DB00233,Aminosalicylic Acid
,32671846,urinary excretion,"Mean urinary excretion of 5-ASA plus N-Ac-5-ASA was comparable between treatments (dose A 21.3%, dose B 20.2%, dose C 17.9%).","Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32671846/),%,17.9,222792,DB00233,Aminosalicylic Acid
,27454774,elimination half-life,The elimination half-life of intravenously administered C2 was approximately 33 min.,Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27454774/),min,33,225325,DB00233,Aminosalicylic Acid
,27454774,Cmax,"The maximum plasma level of C2 was reached approximately 24 min after intragastric administration, with a Cmax value of 2.5 g/mL and an AUCtot value of 157 μg min-1/mL; the oral bioavailability was approximately 13%.",Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27454774/),[g] / [ml],2.5,225326,DB00233,Aminosalicylic Acid
,27454774,AUCtot,"The maximum plasma level of C2 was reached approximately 24 min after intragastric administration, with a Cmax value of 2.5 g/mL and an AUCtot value of 157 μg min-1/mL; the oral bioavailability was approximately 13%.",Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27454774/),[μg] / [min·ml],157,225327,DB00233,Aminosalicylic Acid
,27454774,oral bioavailability,"The maximum plasma level of C2 was reached approximately 24 min after intragastric administration, with a Cmax value of 2.5 g/mL and an AUCtot value of 157 μg min-1/mL; the oral bioavailability was approximately 13%.",Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27454774/),%,13,225328,DB00233,Aminosalicylic Acid
,27454774,unbound fraction,"The plasma protein binding results indicated that the unbound fraction of C2 at concentrations of 1 to 20 μg/mL ranged from 89.8% to 92.5%, meaning that this fraction of C2 is available to cross tissues.",Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27454774/),%,89.,225329,DB00233,Aminosalicylic Acid
,27454774,unbound fraction,"The plasma protein binding results indicated that the unbound fraction of C2 at concentrations of 1 to 20 μg/mL ranged from 89.8% to 92.5%, meaning that this fraction of C2 is available to cross tissues.",Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27454774/),%,92.,225330,DB00233,Aminosalicylic Acid
,27454774,blood-plasma partitioning (BP ratio),"Finally, the blood-plasma partitioning (BP ratio) of C2 in rat plasma was 0.71 and 0.6 at concentrations of 5 and 10 μg/mL, respectively, which indicates that C2 is free in the plasmatic phase and not inside blood cells.",Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27454774/),,0.71,225331,DB00233,Aminosalicylic Acid
,27454774,blood-plasma partitioning (BP ratio),"Finally, the blood-plasma partitioning (BP ratio) of C2 in rat plasma was 0.71 and 0.6 at concentrations of 5 and 10 μg/mL, respectively, which indicates that C2 is free in the plasmatic phase and not inside blood cells.",Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27454774/),,0.6,225332,DB00233,Aminosalicylic Acid
,3319458,steady state plasma levels,Mean steady state plasma levels of unchanged 5-ASA are rather low (range 0.02 to 1.2 microgram/ml) whereas those of Ac-5-ASA are always higher (range 0.1 to 2.9 micrograms/ml).,Pharmacology and pharmacokinetics of 5-aminosalicylic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319458/),[μg] / [ml],0.02 to 1.2,232245,DB00233,Aminosalicylic Acid
,3319458,steady state plasma levels,Mean steady state plasma levels of unchanged 5-ASA are rather low (range 0.02 to 1.2 microgram/ml) whereas those of Ac-5-ASA are always higher (range 0.1 to 2.9 micrograms/ml).,Pharmacology and pharmacokinetics of 5-aminosalicylic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319458/),[μg] / [ml],0.1 to 2.9,232246,DB00233,Aminosalicylic Acid
,3319458,t1/2,"This is due to the rapid elimination of 5-ASA (t1/2 = 0.4 to 2.4h) and the slightly slower renal excretion of the Ac-5-ASA (t1/2 = 6 to 9 h, renal clearance = 200 to 300 ml/min).",Pharmacology and pharmacokinetics of 5-aminosalicylic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319458/),h,0.4 to 2.4,232247,DB00233,Aminosalicylic Acid
,3319458,t1/2,"This is due to the rapid elimination of 5-ASA (t1/2 = 0.4 to 2.4h) and the slightly slower renal excretion of the Ac-5-ASA (t1/2 = 6 to 9 h, renal clearance = 200 to 300 ml/min).",Pharmacology and pharmacokinetics of 5-aminosalicylic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319458/),h,6 to 9,232248,DB00233,Aminosalicylic Acid
,3319458,renal clearance,"This is due to the rapid elimination of 5-ASA (t1/2 = 0.4 to 2.4h) and the slightly slower renal excretion of the Ac-5-ASA (t1/2 = 6 to 9 h, renal clearance = 200 to 300 ml/min).",Pharmacology and pharmacokinetics of 5-aminosalicylic acid. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319458/),[ml] / [min],200 to 300,232249,DB00233,Aminosalicylic Acid
,15586374,Limits' of detection,"Limits' of detection were 5 ng/mL for 5-ASA and 10 ng/mL for acetyl-5-ASA, respectively.",A validated HPLC method with electrochemical detection for simultaneous assay of 5-aminosalicylic acid and its metabolite in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15586374/),[ng] / [ml],5,236457,DB00233,Aminosalicylic Acid
,15586374,Limits' of detection,"Limits' of detection were 5 ng/mL for 5-ASA and 10 ng/mL for acetyl-5-ASA, respectively.",A validated HPLC method with electrochemical detection for simultaneous assay of 5-aminosalicylic acid and its metabolite in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15586374/),[ng] / [ml],10,236458,DB00233,Aminosalicylic Acid
,2295273,peak plasma concentration,The mean peak plasma concentration of N-ac-5-ASA was 1.11 micrograms/ml in Group 1 subjects compared with 2.80 micrograms/ml in Group II subjects (P = N.S.).,The release profile of a controlled release preparation of 5-aminosalicylic acid (Rowasa I) in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295273/),[μg] / [ml],1.11,244957,DB00233,Aminosalicylic Acid
,2295273,peak plasma concentration,The mean peak plasma concentration of N-ac-5-ASA was 1.11 micrograms/ml in Group 1 subjects compared with 2.80 micrograms/ml in Group II subjects (P = N.S.).,The release profile of a controlled release preparation of 5-aminosalicylic acid (Rowasa I) in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295273/),[μg] / [ml],2.80,244958,DB00233,Aminosalicylic Acid
,2295273,recovery,The mean recovery of 5-ASA and N-ac-5-ASA in urine was 8.5 percent in Group I and 35.6 percent in Group II subjects (P less than 0.001).,The release profile of a controlled release preparation of 5-aminosalicylic acid (Rowasa I) in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295273/),%,8.5,244959,DB00233,Aminosalicylic Acid
,2295273,recovery,The mean recovery of 5-ASA and N-ac-5-ASA in urine was 8.5 percent in Group I and 35.6 percent in Group II subjects (P less than 0.001).,The release profile of a controlled release preparation of 5-aminosalicylic acid (Rowasa I) in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295273/),%,35.6,244960,DB00233,Aminosalicylic Acid
,12000534,peak concentrations,"Evaluation of the plasma pharmacokinetics revealed a rapid, but low extent of absorption of OLZ (peak concentrations around 1 microg/mL at 0.5-1.5 h), and a delayed minimal absorption of 5-ASA (concentrations < 0.2 microg/mL, at 11-35 h), which is immediately metabolized to Ac-5-ASA.",Study of the plasma pharmacokinetics and faecal excretion of the prodrug olsalazine and its metabolites after oral administration to horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12000534/),[μg] / [ml],1,245894,DB00233,Aminosalicylic Acid
,12000534,C(max),"As indicators of the local availability in the colon, high faecal water concentrations of 5-ASA and Ac-5-ASA (mean C(max) about 300 and 130 microg/mL, respectively), but only traces of OLZ were found in faeces excreted 18-50 h after dosing.",Study of the plasma pharmacokinetics and faecal excretion of the prodrug olsalazine and its metabolites after oral administration to horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12000534/),[μg] / [ml],300,245895,DB00233,Aminosalicylic Acid
,12000534,C(max),"As indicators of the local availability in the colon, high faecal water concentrations of 5-ASA and Ac-5-ASA (mean C(max) about 300 and 130 microg/mL, respectively), but only traces of OLZ were found in faeces excreted 18-50 h after dosing.",Study of the plasma pharmacokinetics and faecal excretion of the prodrug olsalazine and its metabolites after oral administration to horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12000534/),[μg] / [ml],130,245896,DB00233,Aminosalicylic Acid
,12000534,bioavailability,"The pharmacokinetic evaluation showed a very low bioavailability of 2.4% for 5-ASA, released from orally administered OLZ.",Study of the plasma pharmacokinetics and faecal excretion of the prodrug olsalazine and its metabolites after oral administration to horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12000534/),%,2.4,245897,DB00233,Aminosalicylic Acid
,6391781,elimination half-life,"The effect of renal impairment is relatively unimportant for the excretion of isoniazid, rifampicin and para-aminosalicylic acid, but the elimination half-life of streptomycin increases to 100 hours when the blood urea nitrogen level is greater than 100mg/100ml, and ototoxicity is strikingly more frequent.",Clinical pharmacokinetics of the antituberculosis drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6391781/),h,100,247974,DB00233,Aminosalicylic Acid
up to,6391781,elimination half-life,"Of the data concerning age-related effects, most notable are the prolonged elimination half-life of isoniazid in neonates (up to 19.8 hours), and the lower peak serum concentrations of rifampicin in children of one-third to one-tenth those of adults following a similar dose on a weight basis.",Clinical pharmacokinetics of the antituberculosis drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6391781/),h,19.8,247975,DB00233,Aminosalicylic Acid
,12562452,Cmax,Mean Cmax values (350.6 +/- 322.6 ng/mL) were observed during location in the ileo-caecal region.,Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12562452/),[ng] / [ml],350.6,248892,DB00233,Aminosalicylic Acid
,12562452,relative absorption,The mean relative absorption of 5-ASA was 19.9 +/- 18.2% in the small intestine and ileum and 80.1 +/- 18.2% in the colon.,Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12562452/),%,19.9,248893,DB00233,Aminosalicylic Acid
,12562452,relative absorption,The mean relative absorption of 5-ASA was 19.9 +/- 18.2% in the small intestine and ileum and 80.1 +/- 18.2% in the colon.,Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12562452/),%,80.1,248894,DB00233,Aminosalicylic Acid
,10719917,lower limit of detection,The lower limit of detection was 20 ng/ml in plasma and urine.,Validation of a LC method for the determination of 5-aminosalicylic acid and its metabolite in plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10719917/),[ng] / [ml],20,265613,DB00233,Aminosalicylic Acid
>,7741789,LD50,5-ASA sulfate can be considered as a non-toxic agent after single oral intake in rats (14-day LD50 > 6000 mg/kg b.w.).,Experimental studies on the pharmacokinetics and toxicity of 5-aminosalicylic acid-O-sulfate following local and systemic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741789/),[mg] / [kg],6000,266725,DB00233,Aminosalicylic Acid
,7741789,excretion,"After a single oral administration of 1800 mg 5-ASA sulfate to 5 healthy human test subjects, 5-ASA sulfate was almost completely metabolized by all test subjects within 3 days; mean urinary and faecal excretion of unchanged 5-ASA sulfate amounted to only 6.7% of the administered dose.",Experimental studies on the pharmacokinetics and toxicity of 5-aminosalicylic acid-O-sulfate following local and systemic application. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741789/),%,6.,266726,DB00233,Aminosalicylic Acid
,7848362,half-life,"In faecal suspensions, the half-life of the metabolic conversion of benzalazine was determined as 15 min and the formation of the metabolite 5-aminosalicylic acid (5-ASA) was demonstrated qualitatively.",Pharmacokinetic studies of benzalazine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848362/),min,15,272381,DB00233,Aminosalicylic Acid
